Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T10:55:34.664Z.
Consensus retrieved: 2026-10-06T08:50:40.871Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T10:55:34.664Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2486b729cb124820e370a7041701f0c499bef64609729e12fa9331cc95375005
Forward PE Ratio (N/A) = Dated Quote Price ($2.95) / Consensus Forward EPS ($-0.32)
FORWARD PE RATIO
N/A
Anixa Biosciences, Inc.
Market Cap
$100.37M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Anixa Biosciences, Inc. (ANIX) | $100.37M | N/A |
| Definitive Healthcare Corp. (DH)vs › | $104.07M | 5.06 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.23M | N/A |
| Biomea Fusion, Inc. (BMEA)vs › | $93.99M | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.39M | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.49M | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 7.42 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-10-31
At the dated quote price of $2.95, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-10-31 | $-0.32 | $-0.32 – $-0.32 | 1 | n/m |
| 2027-10-31 | $-0.32 | $-0.32 – $-0.32 | 2 | n/m |
| 2028-10-31 | $-0.34 | $-0.38 – $-0.29 | 3 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
